GlassScriptPhysician profile
Young-In Choi
NPI 1649911744
$1,082.06
in general payments reported to CMS, 2019-2025
10 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 81% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $295.39 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Treace Medical Concepts, INC. | $177.59 | 2025 | |
| Stryker Corporation | $152.64 | 2025 | Augment Injectable |
| Solventum Corporation | $140.78 | 2025 | Prevena, V.A.C.Ulta, Activ.A.C. |
| Avita Medical Americas, LLC | $140.62 | 2025 | Recell |
| Paragon 28, INC. | $70.29 | 2025 | Gorilla |
| Dexcom, INC. | $39.98 | 2025 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $32.93 | 2025 | Qutenza |
| Abbvie INC. | $16.57 | 2025 | |
| Organogenesis INC. | $15.27 | 2025 | Affinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young-In Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.